Tebapivat Drug Asset Due Diligence Report 2026

This Tebapivat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tebapivat can convert its Small molecule drug profile and PKM2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tebapivat (query alias: Tebapivat)
Modality / target	Small molecule drug; PKM2; PKM2 stimulants
Highest global status	Phase 2
Originator	Agios Pharmaceuticals, Inc.
Active developers	Agios Pharmaceuticals, Inc., University of Utrecht, University Medical Center of Utrecht

The MCP disease footprint includes Anemia, Myelodysplastic Syndromes, Anemia, Sickle Cell. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06924970	Phase 2	Terminated	59	Primary endpoint not disclosed in English source
NCT06745271	Phase 1	Completed	8	Primary endpoint not disclosed in English source
NCT05490446	Phase 2	Active, not recruiting	87	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

2496Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Phase 1; n=not disclosed; evaluation: Not stated in English source. Reported fields: ATP = 46.3 % ( 29.08); ATP = 67.8 % ( 30.92)

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Phase 2; n=22; evaluation: Positive. Reported fields: TI = 4 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tebapivat addresses Anemia, Myelodysplastic Syndromes, Anemia, Sickle Cell. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “target-level comparable: PKM2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PKM2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2023-09-12	Avalo Enters into Agreement to Divest AVTX-800 Series	Phase 3	US$0.1M upfront; US$45.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of the pyruvate kinase activator tebapivat in the treatment of renal fibrosis and other renal diseases”. The milestone feed surfaced a patent-application signal described as “Use of a PK activator in the treatment of sickle cell disease”. The milestone feed surfaced a patent-application signal described as “Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-YL)methyl)-6-((6-aminopyridin-2-YL)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO